WASHINGTON — The Food and Drug Administration approved a new cholesterol-lowering drug called Vytorin, the drug’s maker announced Friday.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The pill, manufactured and marketed by a joint venture between Merck & Co. Inc. and Schering-Plough Corp., is a combination of two other cholesterol drugs, Zetia and Zocor.
Vytorin has been shown in studies to lower cholesterol better than market leader Lipitor, which holds a 55 percent share of prescriptions and 49 percent of sales.
Zocor is from the class of drugs known as statins, and lowers cholesterol by cutting its production in the liver. Zetia, meanwhile, limits the absorption of cholesterol in the intestines.
Vytorin’s approval coincides with the release last week of new guidelines that call for high-risk heart patients to lower their so-called bad cholesterol, or LDL, to 70 instead of 100 as previously recommended.
The FDA was not immediately available for comment.
© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.